Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs Banco Santander SA (SAN) Price & Performance

ResMed Inc.Trade
Banco Santander SATrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs Banco Santander SA — how do they compare? ResMed Inc. trades at $225.36 (market cap $32.61B), while Banco Santander SA trades at $14.81 (market cap $211.63B). The key difference: Banco Santander SA is far larger — about 6.5× ResMed Inc.'s market cap, and Banco Santander SA pays the higher dividend (1.89%). Which is the better fit depends on your goals.

RMDSAN
Market Cap
$32.61B$211.63B
Sector
HealthFinancials
52-Week High
$293.73$14.71
52-Week Low
$182.82$9.37
Enterprise Value
$31.97B
Dividend Yield
1.17%1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.

Banco Santander SA

Santander (SAN) trades at $14.80, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a 26.25% net income margin and a P/E of 14.4. Recent news includes Federal Reserve approval for its $12 billion acquisition of Webster Bank, expected to close in August 2026, which may enhance its US market presence.

The outlook is positive, supported by analyst consensus (64% buy ratings) and record profitability. Key risks include volatile cash flows, with negative net cash flow in 2024, and integration challenges from the Webster deal. Revenue growth remains a catalyst, but investors should monitor execution risks and macroeconomic pressures on banking sectors.

Returns comparison

Trailing returns across standard periods

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About Banco Santander SA

Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.

Read more on SAN